FDA Approves KRYSTEXXA (pegloticase) Injection Co-Administer

FDA Approves KRYSTEXXA (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

08.07.2022 - Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) expanding the labeling to include KRYSTEXXA (pegloticase) injection ... Seite 1

Related Keywords

Alaska , United States , Johnk Botson , , Alaska Rheumatology Alliance , Orthopedic Physicians , Horizon Therapeutics ,